Kiavasch Mohammad Nejad Farid, MD, discussed the clinical utility of tabelecleucel in relapsed/refractory post-transplant lymphoproliferative disorder.
Kiavasch Mohammad Nejad Farid, MD
Advertisement
Kiavasch Mohammad Nejad Farid, MD, of Heidelberg University Hospital.
Articles by Kiavasch Mohammad Nejad Farid, MD
Kiavasch Mohammad Nejad Farid, MD, discusses 2 planned investigations of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and AL amyloidosis.
Kiavasch Mohammad Nejad Farid, MD, discusses how compassionate use of MDC-CAR-BCMA001 could address unmet needs for multiple myeloma and AL amyloidosis.
Kiavasch Mohammad Nejad Farid, MD, discusses the efficacy of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and systemic light chain (AL) amyloidosis.
Advertisement
Latest Updated Articles
Dr Farid on the Efficacy of MDC-CAR-BCMA001 in R/R Myeloma and AL AmyloidosisPublished: April 3rd 2025 | Updated:
Dr Farid on the Rationale for Evaluating MDC-CAR-BCMA001 in R/R Myeloma and AL AmyloidosisPublished: April 16th 2025 | Updated:
Dr Farid on Current and Future Investigations of MDC-CAR-BCMA001 in Myeloma and AL AmyloidosisPublished: April 22nd 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5